U.S. Markets closed

Idera Pharmaceuticals reports top-line results from Phase 2 trial of IMO-2055

Idera Pharmaceuticals announced top-line results of a randomized, controlled Phase 2 clinical trial of IMO-2055, the company's investigational oncology product candidate targeting Toll-like Receptor 9 in combination with Erbitux for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck in patients who previously progressed on chemotherapy. The study did not meet its primary endpoint of improved progression-free survival following treatment with IMO-2055 in combination with cetuximab compared to treatment with cetuximab alone. The median progression-free survival based on investigator assessments was 2.9 months in both arms; based on independent radiology review, it was 1.9 months in the cetuximab arm and 1.5 months in the combination arm.